PrEP at IAS 2017 / IAS Coverage
Safety and acceptability trial of the dapivirine vaginal ring in U.S. adolescents - Dapivirine Vaginal Ring Safe and Acceptable in US Adolescents - (08/07/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
An Open Label Multiple Dose Phase 1 Assessment of Long Acting Rilpivirine - Long-Acting Rilpivirine Suppresses Replication in Rectal Explants - Mark (08/07/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
One-year experience with Pre-Exposure Prophylaxis (PrEP) Implementation in France with TDF/FTC - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Is on-demand PrEP with TDF/FTC effective among MSM with infrequent sexual intercourse? - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Potential for HIV transmission among adolescents and young adults receiving antiretroviral therapy - 'PrEP missed opportunities' - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Impact of microbiota on female genital tissue and plasma concentrations of dapivirine - (08/02/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Limited implementation of HIV pre-exposure prophylaxis among public health departments in North Carolina, United States - (08/02/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Changes in Truvada® for HIV Pre-exposure Prophylaxis Utilization in the USA: 2012-2016 - Disparities - (08/02/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Reasons for not using PrEP in a national on-line sample of U.S. men who have sex with men (MSM) - Cost, Side Effects, Access Lead Reasons for PrEP Nonuse by US MSM  - (07/31/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Experiences and perceptions of PrEP among gay, MSM, and TGW in the PROUD study in England: 'Rules' of Sex, Psychological, Psychosocial Benefits -  (07/31/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Adherence intentions, long-term adherence and HIV acquisition among PrEP users in the PROUD open-label randomised control trial of PrEP in England - (07/31/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Long term follow up of PROUD Evidence for high continued HIV exposure and durable effectiveness of PrEP - (07/31/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Is on-demand PrEP a suitable tool for MSM who practice chemsex? Results from a sub-study of the ANRS-IPERGAY trial - Chemsex Users in IPERGAY Twice as Likely to Use As-Needed PrEP -  (07/28/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
No HIV Transmissions in Gay Couples if HIV+ Partner Has Undetectable Virus -  (07/27/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Impact of risk perception trajectory on PrEP and condom use among Men who have Sex with Men during the Open-Label-Extension of the ANRS-IPERGAY trial - (07/27/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Single Doses as Low as 0.5 mg of the Novel NRTTI MK-8591 Suppress HIV for At Least Seven Days - (07/26/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Weekly Oral MK-8591 Protects Male Rhesus Macaques against Repeated Low Dose Intrarectal Challenge with SHIV109CP3 - (07/23/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
A Single Monotherapy Dose of MK-8591,a Novel NRTI, Suppresses HIV for Ten Days - (02/24/16)
Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA
Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis - (02/24/16)
Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA
   
News Updates

Researchers adapt CAR-T immunotherapy to target the HIV latent reservoir 

Medical Xpress | October 24, 2019

NIH Launches New Collaboration to Develop Gene-Based Cures for Sickle Cell Disease and HIV on Global Scale

HIV.gov | October 24, 2019

NIH launches new collaboration to develop gene-based cures for sickle cell disease and HIV on global scale

NIH | October 23, 2019

Drug reverses signs of liver disease in people living with HIV

NIH | October 15, 2019

The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy

AIDS Res Hum Retroviruses. 2019 Oct 14. doi: 10.1089/AID.2019.0175

Study demonstrates antibody responses within 6 weeks of initial vaccination 

EurekAlert | October 1, 2019

AIDS Treatment: Russian Researchers Create New Medications 

QS WOW News | September 29, 2019

UAB researchers land funding to combat HIV 

Birmingham Business Journal | September 27, 2019

UC San Diego Researchers Isolate Switch that Kills Inactive HIV 

UC San Diego Health | September 24, 2019

Papillomaviruses May Be Able To Be Spread By Blood

EurekAlert | September 11, 2019

CRISPR shown to be safe to target HIV (but unsuccessful so far) 

The Daily Briefing | September 13, 2019

An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals

Science Translational Medicine | September 7, 2019

The disconnect between individual-level and population-level HIV prevention benefits of antiretroviral treatment 

The Lancet | September 2019

Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities 

The Lancet | September 2019

Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.

Clin Infect Dis. 2018 Jan 6;66(2):213-219. doi: 10.1093/cid/cix755.

Cellular therapies are the next big step in fight against HIV/Aids 

Independent Online | August 31, 2019

Animal activists are on the wrong side of the fight against AIDS 

STAT | August 30, 2019

Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection

BusinessWire | August 28, 2019

Repeated semen exposure promotes host resistance to infection in preclinical HIV model 

EurekAlert | August 21, 2019

New Molecule Identified That May Further Suppress Effectively Treated HIV

POZ | August 14, 2019

Cancer therapy returns to original target: HIV 

Science Magazine | August 9, 2019

HOPE trial: Dapivirine vaginal ring reduces HIV risk by estimated 39% 

Healio | August 6, 2019

Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV

JCI | July 22, 2019

Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen’s Investigational Prophylactic HIV Vaccine

IAS 2019: Conference on HIV Pathogenesis Treatment and Prevention, Mexico City, July 21-24 2019

PrEP use high but wanes after three months among young African women

NIH | July 23, 2019

Developing a novel HIV vaccine: DNA and recombinant proteins 

Science Daily | July 23, 2019

Duke Human Vaccine Institute receives $129 million grant for HIV/AIDS research 

Duke Chronicle | July 19, 2019

HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa

New England Journal of Medicine | July 18, 2019

Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071 (PopART)

New England Journal of Medicine | July 18, 2019

Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana

New England Journal of Medicine | July 18, 2019

HIV-1 Epidemic Control — Insights from Test-and-Treat Trials, Slim Abdool Karim

New England Journal of Medicine | July 18, 2019

Acceptability and Preferences for Long-Acting Antiretroviral Formulations Among People Living with HIV infection

IAPAC Adherence June 17-19 Miami

Enlisting CRISPR in the Quest for an HIV Cure

NIH | July 16th, 2019

Johnson & Johnson to start testing on new type of HIV vaccine in US and Europe 

New York Daily News | July 13, 2019

Consortium Led by Scripps Research Gets $129 Million for HIV/AIDS Vaccine Clinical Trials 

Times of San Diego | July 10, 2019

HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya

Trials. 2019 Jul 4;20(1):396. doi: 10.1186/s13063-019-3521-2.

HIV eliminated from the genomes of living animals

Nature Communications | June 2019

Genotype Testing at HIV Diagnosis Provides No Benefit 

Infectious Disease Advisor | June 24, 2019

Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection

Science Translational Medicine | June 15, 2019

AIDSinfo Updates Investigational HIV Drug Fact Sheets

AIDSinfo | June 14, 2019

Women and Clinical Trials

The New York Times | June 14, 2019

GSK partners with CRISPR pioneer Doudna to search for new drugs

STAT News | June 13, 2019

Durable Control of HIV Infection in the Absence of Antiretroviral Therapy - Opportunities and Obstacles

Viewpoint | June 6, 2019

Trump administration imposes new restrictions on fetal tissue research

Washington Post | June 5, 2019

Statement from the Department of Health and Human Services

HHS.gov | June 5, 2019

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

JAMA Oncol. Published online June 2, 2019

HIV Vaccine Awareness Day 2019 — May 18, 2019

National Institutes of Health | May 17, 2019

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from ...

Yahoo Finance | May 13, 2019

NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens - LATITUDE study compares monthly injectable antiretroviral therapy to daily oral drugs

NIH | May 9, 2019

NIH awards will advance development of vaccines for sexually transmitted infections

NIH | May 5, 2019

Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base

Cancer. 2019 May 3. doi: 10.1002/cncr.32158

Boston hospital receives largest philanthropic gift in history for HIV/AIDS vaccine research

WCVB Boston | April 25, 2019

Novel antibody may suppress HIV for up to four months

NIH | April 17, 2019

Scientists find another way HIV can hide from vaccines

Yale News | April 10, 2019

Orion Biotechnology to Present OB-002 in Vitro Potency Data at the 10th International AIDS Society HIV Science Meeting in Mexico City in July 2019

PR Newswire | March 28, 2019

Aaron Diamond AIDS Research Center to Join Columbia University

Columbia University | March 20, 2019

Curing HIV just got more complicated. Can CRISPR help?

Science Magazine | March 15, 2019

Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach

PLoS Med. 2019 Mar 4;16(3):e1002756. doi: 10.1371/journal.pmed.1002756. eCollection 2019 Mar.

This is Not A Cure for My H.I.V.

New York Times | March 9, 2019

One step closer to ultra-long-acting PREP?

AIDS: march 2019

New Target for HIV Immune Therapy and Cure to be Explored by Trans-Atlantic Industry-Academia Collaboration

NATAP | February 20th, 2019

Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge

Nat Commun. 2019 Feb 18;10(1):798. doi: 10.1038/s41467-019-08739-4

NIH Clinical Trial to Track Outcomes of Liver Transplantation from HIV-Positive Donors to HIV-Positive Recipients

HIV.gov | February 15, 2019

Ending the HIV Epidemic: A Plan for the United States

NIH | February 7, 2019

Study of PrEP and vaginal ring for HIV prevention begins in girls and young women

NIH | February 7, 2019

HIV-AIDS drug could help treat Alzheimer's and other age-related diseases, Brown researchers say

The Providence Journal | February 6, 2019

Hodgkin's lymphoma and its association with EBV and HIV infection

Crit Rev Clin Lab Sci. 2018 Mar;55(2):102-114. doi: 10.1080/10408363.2017.1422692. Epub 2018 Jan 9

Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer

A Systematic Review

Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation

BMJ Open. 2019 Jan 17;9(1):e024793. doi: 10.1136/bmjopen-2018-024793.

Heterosexual oral and anal sex in Kinshasa (D.R.Congo): Data from OKAPI prospective cohort

PLoS One. 2019 Jan 16;14(1):e0210398. doi: 10.1371/journal.pone.0210398. eCollection 2019

Incidence and Correlates of STIs among Black Men who have Sex with Men Participating in the HPTN 073 PrEP Study.

Clin Infect Dis. 2019 Jan 7. doi: 10.1093/cid/ciy1141.

Scientists achieve the first proof of concept for an HIV broadly-neutralising antibody vaccine in ...

aidsmap | January 2, 2019

Potential of HIV-Protective Drugs Administered Via Rectal Douches

Infectious Disease Advisor | December 26, 2018

AIDS -- an approach for targeting HIV reservoirs

Eurek Alert | December 20, 2018

AIDS: An approach for targeting HIV reservoirs

Science Daily | December 20, 2018

Study Determines Why Patients With HIV Have Higher Rates of Cancer

AJMC.com Managed Markets Network | December 14, 2018

NIH to fund HIV care and prevention research in the South

Healio | December 14, 2018

Removable PrEP implant produces high drug levels in rabbits; further studies planned

aidsmap | November 15, 2018

Johns Hopkins researchers examine testosterone use to increase BMD in HIV-infected men

EurekAlert | December 12, 2018

A protein complex from human milk enhances the activity of antibiotics and drugs against Mycobacterium tuberculosis

Antimicrob Agents Chemother. 2018 Nov 12. pii: AAC.01846-18. doi: 10.1128/AAC.01846-18

With HIV/AIDS Research Threatened, NIH Looks For Stem-Cell Alternatives

Rolling Stone | December 11, 2018

Uganda starts tests for long acting injectable ARVs

New Vision | November 9, 2018